文献速递免疫规划传染病防控与疫情报告

婴儿PCV7/PCV13序贯接种对成人侵袭性肺炎球菌疾病的群体效应:实施后六年以色列全国性研究

The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
PubMed 文献 · Vaccine · 2017-03-22

以色列2009年7月启动全国主动监测,婴儿接种PCV7后于2010年11月逐步替换为PCV13。成人IPD总发病率在PCV13实施后降至7.19/10万并保持稳定,PCV7-VT和PCV13-VT IPD分别下降79%和71%,但非PCV13型IPD上升,≥65岁成人PCV13-VT IPD下降幅度较小(65% vs <50岁成人>80%)。

要点

  • PCV7-VT IPD发病率从2.52降至0.52/10万(降79%),PCV13-VT从6.15降至1.81/10万(降71%)。
  • 非PCV13型IPD发病率从2.99升至5.25/10万,导致总IPD发病率近两年保持稳定。
  • ≥65岁成人PCV13-VT IPD下降65%,小于50岁成人下降超过80%。

核心结论

  • 尽管PCV13-VT IPD持续下降,但由于血清型替换,总IPD发病率在最后两年保持稳定。
  • PCV7/PCV13实施后六年成人IPD显著下降,强调间接保护对实现总体人群影响的重要性,讨论成人直接接种PCV的潜在额外获益时应考虑此点。

研究设计与样本

  • 全国性主动监测,2009年7月启动,随访至2015年,纳入成人>18岁人群(5.0–5.5百万),诊断2579例IPD。
  • PCV7于2009年7月实施(含补接种),PCV13自2010年11月起逐步替换PCV7。
  • 从医疗档案收集合并症和结局数据,计算总体和疫苗型IPD发病率。

主要发现

  • 成人IPD发病率第一研究年为9.15/10万,第二年为10.16/10万。
  • PCV13实施后四年内发病率降至7.19/10万,随后两年保持稳定。
  • 六年内PCV7-VT IPD发病率从2.52降至0.52/10万(降79%),PCV13-VT IPD从6.15降至1.81/10万(降71%)。
  • 同期非PCV13型IPD发病率从2.99升至5.25/10万。
  • 约50%患者为≥65岁成人,其PCV13-VT IPD发病率下降幅度较小且较慢(65% vs 小于50岁成人>80%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Introduction of pneumococcal conjugate vaccine (PCV) has nearly eliminated vaccine-type (VT) invasive pneumococcal disease (IPD) in children, yet the reported resulting reduction of adult IPD is variable. We present the indirect impact of sequential PCV7/PCV13 implementation in Israel on adult IPD. METHODS: An ongoing nationwide active surveillance was initiated on July 2009 when PCV7 was implemented (with Catch-up). PCV7 was gradually replaced by PCV13 since November 2010. Comorbidity and outcome data were collected from medical files. Incidence rates were calculated for overall and vaccine-type IPD. RESULTS: A total of 2579 IPD cases were diagnosed among a population of 5.0-5.5 million adults >18y (2009-2015). Incidence rates were 9.15/100,000 and 10.16/100,000 in the first and second study years, respectively. However, after PCV13 implementation, the rates decreased to 7.19 within four years, and remained stable in the two following years. Within 6years, PCV7-VT-IPD incidence decreased from 2.52 to 0.52 (79%) and PCV13-VT-IPD from 6.15 to 1.81 (71%). Concurrently, non-VT13 incidence increased from 2.99 to 5.25. Approximately 50% of all patients were adults ≥65y, in whom the decrease in PCV13-VT-IPD incidence was smaller and slower (65% vs. >80% decrease in adults <50y). CONCLUSIONS: Despite continued reduction in PCV13-VT-IPD, overall IPD was stable during the last two years due to serotype replacement. Yet, the significant decrease in adult IPD, six years post-PCV7/13 implementation emphasizes the importance of indirect protection in achieving overall population impact and should be considered when discussing the potential additional benefits of direct adult PCV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Regev-Yochay G, Katzir M, Strahilevitz J, et al. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel. Vaccine. 2017. PMID: 28342668. doi:10.1016/j.vaccine.2017.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。